Javascript must be enabled to continue!
Emergency Department Time Targets for Interhospital Transfer of Patients with Acute Ischemic Stroke
View through CrossRef
Background and objectives: Although the intravenous tissue plasminogen activator (rt-PA) has been shown to be effective in the treatment of acute ischemic stroke (AIS), only a small proportion of stroke patients receive this drug. The low administration rate is mainly due to the delayed presentation of patients to the emergency department (ED) or the lack of a stroke team/unit in most of the hospitals. Thus, the aim of this study is to analyze ED time targets and the rate of rt-PA intravenous administration after the initial admission of patients with AIS in an ED from a traditional healthcare center (without a neurologist or stroke team/unit). Methods: To analyze which factors influence the administration of rt-PA, we split the general sample (n = 202) into two groups: group No rt-PA (n = 137) and group rt-PA (n = 65). This is based on the performing or no intravenous thrombolysis. Results: Analyzing ED time targets for all samples, we found that the median onset-to-ED door time was 180 min (IQR, 120–217.5 min), door-to-physician time was 4 min (IQR, 3–7 min), door-to-CT time was 52 min (IQR, 48–55 min), and door-in-door-out time was 61 min (IQR, 59–65 min). ED time targets such as door-to-physician time (p = 0.245), door-to-CT time (p = 0.219), door-in-door-out time (p = 0.24), NIHSS at admission to the Neurology department (p = 0.405), or NIHSS after 24 h (p = 0.9) did not have a statistically significant effect on the administration or no rt-PA treatment in patients included in our study. Only the highest door-to-CT time was statistically significantly correlated with the death outcome. Conclusion: In our study, the iv rt-PA administration rate was 32.18%. A statistically significant correlation between the highest door-to-CT time and death outcome was found.
Title: Emergency Department Time Targets for Interhospital Transfer of Patients with Acute Ischemic Stroke
Description:
Background and objectives: Although the intravenous tissue plasminogen activator (rt-PA) has been shown to be effective in the treatment of acute ischemic stroke (AIS), only a small proportion of stroke patients receive this drug.
The low administration rate is mainly due to the delayed presentation of patients to the emergency department (ED) or the lack of a stroke team/unit in most of the hospitals.
Thus, the aim of this study is to analyze ED time targets and the rate of rt-PA intravenous administration after the initial admission of patients with AIS in an ED from a traditional healthcare center (without a neurologist or stroke team/unit).
Methods: To analyze which factors influence the administration of rt-PA, we split the general sample (n = 202) into two groups: group No rt-PA (n = 137) and group rt-PA (n = 65).
This is based on the performing or no intravenous thrombolysis.
Results: Analyzing ED time targets for all samples, we found that the median onset-to-ED door time was 180 min (IQR, 120–217.
5 min), door-to-physician time was 4 min (IQR, 3–7 min), door-to-CT time was 52 min (IQR, 48–55 min), and door-in-door-out time was 61 min (IQR, 59–65 min).
ED time targets such as door-to-physician time (p = 0.
245), door-to-CT time (p = 0.
219), door-in-door-out time (p = 0.
24), NIHSS at admission to the Neurology department (p = 0.
405), or NIHSS after 24 h (p = 0.
9) did not have a statistically significant effect on the administration or no rt-PA treatment in patients included in our study.
Only the highest door-to-CT time was statistically significantly correlated with the death outcome.
Conclusion: In our study, the iv rt-PA administration rate was 32.
18%.
A statistically significant correlation between the highest door-to-CT time and death outcome was found.
Related Results
Iranian stroke model-how to involve health policymakers
Iranian stroke model-how to involve health policymakers
Stroke in Iran, with more than 83 million population, is a leading cause of disability and mortality in adults. Stroke has higher incidence in Iran comparing the global situation a...
Comparative Characterization of Candidate Molecular Markers in Ischemic and Hemorrhagic Stroke
Comparative Characterization of Candidate Molecular Markers in Ischemic and Hemorrhagic Stroke
According to epidemiological studies, the leading cause of morbidity, disability and mortality are cerebrovascular diseases, in particular ischemic and hemorrhagic strokes. In rece...
Prevalence of Diabetes Mellitus in Acute Ischemic Stroke Patients at Tertiary Care Hospital
Prevalence of Diabetes Mellitus in Acute Ischemic Stroke Patients at Tertiary Care Hospital
Back ground: The third largest cause of death around the globe is stroke. In the United States the largest cause of disability is also stroke. For stroke and coronary heart diseas...
Abstract TP158: High Mortality In In-Hospital-Stroke Patients After Interhospital Transfer For Endovascular Therapy
Abstract TP158: High Mortality In In-Hospital-Stroke Patients After Interhospital Transfer For Endovascular Therapy
There are only few studies examining In-Hospital-Stroke- (IHS) patients with a large vessel occlusion and subsequent transfer to a comprehensive stroke center for endovascular ther...
Abstract TP294: The Impact of Chronic Kidney Disease Severity on Incident Acute Ischemic Stroke
Abstract TP294: The Impact of Chronic Kidney Disease Severity on Incident Acute Ischemic Stroke
Introduction:
Chronic kidney disease (CKD) and ischemic stroke are both associated with significant global disease burdens and share common risk factors. Understanding ...
Clinical Features, Risk Factors and Hospital Mortality of Acute Stroke Patients
Clinical Features, Risk Factors and Hospital Mortality of Acute Stroke Patients
Background: Stroke is a leading cause of mortality and disability worldwide. To prevent complications and permanent defects, early diagnosis, distinguishing the type and risk facto...
HIPERTENSI, USIA, JENIS KELAMIN DAN KEJADIAN STROKE DI RUANG RAWAT INAP STROKE RSUD dr. M. YUNUS BENGKULU
HIPERTENSI, USIA, JENIS KELAMIN DAN KEJADIAN STROKE DI RUANG RAWAT INAP STROKE RSUD dr. M. YUNUS BENGKULU
Hypertension, Age, Sex, and Stroke Incidence In Stroke Installation Room RSUD dr. M. Yunus BengkuluABSTRAKStroke adalah gejala-gejala defisit fungsi susunan saraf yang diakibatka...
Raising pre-transfusion HbS levels from 30% to 50% does not increase ischemic stroke recurrence in sickle cell disease: Results from a long-term single-center study
Raising pre-transfusion HbS levels from 30% to 50% does not increase ischemic stroke recurrence in sickle cell disease: Results from a long-term single-center study
Abstract
Introduction: Exchange transfusion remains the only strategy for the secondary prevention of ischemic stroke in...

